NEW YORK (GenomeWeb) – C2N Diagnostics today announced the expansion of a partnership with Washington University School of Medicine in St. Louis to commercialize a clinical blood test for the detection of Alzheimer's disease at its earliest stages, as well as mild cognitive impairment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.